Nautilus Biotechnology, Inc.
NASDAQ:NAUTBiotechnology
+$0.05 today
- Market cap
- $309.51M
- Beta
- 0.75
- P/E (TTM)
- -4.9
- EPS (TTM)
- -$0.45
Volume 4.55M
Average 0.40M
NAUT EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Nautilus Biotechnology, Inc.NASDAQ: NAUT
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$13.22M, compared with -$14.99M a year earlier. Trailing-twelve-month EBITDA was -$50.77M.
Context
- EBITDA grew in size in 2 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 2 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the +18.5% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$13.22M-8.4% QoQ
- Last fiscal yearDec 2025
- -$52.54M+18.5% YoY
- LTMMar 2026
- -$50.77M+11.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +11.8% | +100.0% | +88.2 pp |
| 1 year | +18.5% | +100.0% | +81.5 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (52.54M) USD
- Year-over-year change
- +18.5%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (52.54M) | +18.5% |
| FY2024 | 2024-12-31 | (64.43M) | -4.2% |
| FY2023 | 2023-12-31 | (61.83M) | -13.4% |
| FY2022 | 2022-12-31 | (54.51M) | -14.8% |
| FY2021 | 2021-12-31 | (47.47M) | — |
EBITDA vs competitors
How NAUT compares with its peers on the latest reported figures
- NAUT's LTM Mar 2026 EBITDA of -$50.77M is the 4th highest of the 11 companies compared; the peer median is -$70.03M.
- Its year-over-year change of +11.7% is the 5th highest of 11, against a peer median of +7.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$6.26M | +84.1% | — | 8.8% | |
SGMTSagimet Biosciences Inc. | LTM Mar 2026 | -$46.14M | +19.2% | — | — |
| LTM Mar 2026 | -$46.56M | +46.6% | — | 67.3% | |
| LTM Mar 2026 | -$50.77M | +11.7% | — | — | |
| LTM Mar 2026 | -$58.85M | +7.0% | — | — | |
| LTM Mar 2026 | -$67.53M | -3.7% | — | 148.9% | |
| LTM Mar 2026 | -$72.53M | +7.7% | — | 257.0% | |
ZURAZura Bio Limited | LTM Mar 2026 | -$75.38M | -21.4% | — | — |
| LTM Mar 2026 | -$75.47M | +22.0% | — | 33540.9% | |
| LTM Mar 2026 | -$75.93M | +0.5% | — | 547.9% | |
| LTM Mar 2026 | -$79.77M | -33.1% | — | 3956.7% | |
| Peer median (excluding NAUT) | -$70.03M | +7.3% | — | 257.0% | |
Competitors are the stored peer set for NAUT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 2.84M | 3.42M | 5.71M | 6.35M | 6.47M |
| Gross Profit | (2.84M) | (3.42M) | (5.71M) | (6.35M) | (6.47M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 26.51M | 36.46M | 47.25M | 50.48M | 41.11M |
| Selling, General & Admin | 21.15M | 23.75M | 28.9M | 31M | 25.73M |
| Operating Expenses | 47.66M | 60.2M | 70.45M | 75.12M | 60.37M |
| Depreciation & Amortization | 2.84M | 3.42M | 1.85M | 6.35M | 6.47M |
| EBITDA | (47.47M) | (54.51M) | (61.83M) | (64.43M) | (52.54M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (50.5M) | (63.62M) | (76.15M) | (81.48M) | (66.84M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 329K | 5.82M | 12.55M | 10.78M | 7.87M |
| Interest Expense | 0 | 5.82M | 0 | 0 | 0 |
| Other Income / Expenses | 183K | 5.69M | 12.48M | 10.7M | 7.84M |
| Income Before Tax | (50.32M) | (57.92M) | (63.68M) | (70.78M) | (59M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (50.32M) | (57.92M) | (63.68M) | (70.78M) | (59M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.60) | (0.46) | (0.51) | (0.56) | (0.47) |
| EPS (Diluted) | (0.60) | (0.46) | (0.51) | (0.56) | (0.47) |
| Weighted Avg Shares | 84.46M | 124.59M | 124.92M | 125.43M | 126.26M |
| Weighted Avg Shares (Diluted) | 84.46M | 124.59M | 124.92M | 125.43M | 126.26M |
Nautilus Biotechnology, Inc.
NASDAQ:NAUT
Intrinsic Alpha fair value
Locked
Current Price
$2.43
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.